COPD
Conditions
Interventions
COPD patients using Dupilumab:NA
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: Patients aged 18-80 years diagnosed with chronic obstructive pulmonary disease (COPD) according to the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; 2: Patients who have received conventional treatment but still exhibit poor symptom control and/or have experienced at least one acute exacerbation in the past year, or are at high risk of acute exacerbation; 3: Patients meeting at least one of the following type 2 inflammation diagnostic criteria: Blood eosinophil count >=150 cells/µL FeNO level >=25 ppb Sputum eosinophil level >=2% Allergen testing: total IgE level >=100 kU/L or specific IgE level >=0.35 IU/L (within the past year); 4: Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1: Comorbidities with other severe respiratory diseases; 2: Hypersensitivity to dupilumab or its excipients; 3: Pregnant or breastfeeding women; 4: Other conditions deemed unsuitable for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| acute exacerbation rate change; | — |
Secondary
| Measure | Time frame |
|---|---|
| FEV1, FVC change;CAT,SGRQ scores change;Incidence of adverse events over up to 52-week Dupilumab treatment period.;EOS, FeNO, IgE change;the proportion of patients achieving clinical remission with dupilumab in a real-world setting;Clinical treatment costs during dupilumab therapy; | — |
Countries
China
Contacts
Public ContactMin Tan
Shanghai Tenth People's Hospital
Outcome results
None listed